Overview

Safety of Topical Tranexamic Acid in Total Joint Arthroplasty in High Risk Patients

Status:
Withdrawn

Trial end date:
2019-01-01

Target enrollment:
0

Participant gender:
All

Summary

To evaluate whether there is a difference in symptomatic thromboembolism events in the subset of patients with a history of, or risk factors for thromboembolic disease for topically applied tranexamic acid in total joint arthroplasty.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Albert Einstein College of Medicine
Albert Einstein College of Medicine of Yeshiva University

Treatments:

Tranexamic Acid

Criteria

Inclusion Criteria:

Presence of one or more of seven risk factors for thromboembolic events - Prior DVT, PE,
MI, CVA, coronary artery stent placement, CABG, or prothrombotic condition (Factor V Leiden
deficiency, protein C deficiency, antiphospholipid syndrome, etc).

Exclusion Criteria:

Simultaneous bilateral, hip resurfacing, partial knee, and revision arthroplasties